Nevertheless, one phase I/II nonrandomized trial in stage IV renal cell cancer patients vaccinated with mRNA that codes the same tumour antigens for GBM patients, including MAGE-1, Survivin, and HER-2, reported favourable clinical benefits.87 This evidence concerns the gene ERBB2 and glioblastoma.